| Year |
Citation |
Score |
| 2017 |
Doi T, Yamaguchi K, Komatsu Y, Muro K, Nishina T, Nakajima TE, Tang R, Yang H, Zhang Y, Jung AS, Ang A, Yasui H. A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer. Japanese Journal of Clinical Oncology. 1-8. PMID 28973403 DOI: 10.1093/jjco/hyx114 |
0.316 |
|
| 2017 |
Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 28601388 DOI: 10.1016/j.cllc.2017.05.007 |
0.347 |
|
| 2008 |
Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 1903-9. PMID 18632723 DOI: 10.1093/Annonc/Mdn412 |
0.399 |
|
| 2001 |
Zhang Y, Song S, Yang F, Au JL, Wientjes MG. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. The Journal of Pharmacology and Experimental Therapeutics. 299: 426-33. PMID 11602651 |
0.439 |
|
| Show low-probability matches. |